Drug intelligence / Profile preview

tenofovir disoproxil fumarate + peginterferon alfa-2a

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral, Subcutaneous

Overview

A combination therapy consisting of tenofovir disoproxil fumarate (TDF) and peginterferon alfa-2a. TDF is a nucleotide analog reverse transcriptase inhibitor that blocks HBV DNA polymerase, inhibiting viral replication. Peginterferon alfa-2a is a pegylated form of recombinant human interferon that stimulates the innate antiviral immune response by binding to type 1 interferon receptors and activating the JAK/STAT pathway, leading to expression of interferon-stimulated genes with antiviral properties. This combination has shown superior efficacy in achieving hepatitis B surface antigen (HBsAg) loss compared to either agent alone in chronic hepatitis B patients.

Brand names: VireadPegasys
Other names: PEG-Interferon Alfa + Tenofovir Disoproxil Fumaratepegylated interferon alpha + tenofovir disoproxil fumaratePEG-IFNα + TDFPegIFN-α + TDF

Targets

HBV Pol (Hepatitis B virus polymerase)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)S100A8 (S100 calcium-binding protein A8)

Beyond the preview

Go deeper on tenofovir disoproxil fumarate + peginterferon alfa-2a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tenofovir disoproxil fumarate + peginterferon alfa-2a.

Explore the full profile